L-Leucine 是一种必需的支链氨基酸 (BCAA)，可激活mTOR信号通路。
| 生物活性 | L-Leucine is an essential branched-chain amino acid (BCAA), which activates themTORsignaling pathway[1]. |
| IC50& Target[1][2] | mTORC1 | Human Endogenous Metabolite | Microbial Metabolite |
|
体外研究
(In Vitro) | L-Leucine (10 mM) treatment impairs endocrine progenitor cell development[1].
In E13.5 rat pancreatic explants, in absence of added L-Leucine,Ngn3mRNA levels increased after 1 day of culture, peaked on day 3, and then decreased. When L-Leucine is added, a dramatic decrease is observed inNgn3mRNA levels. This decrease in Ngn3 mRNA levels was paralleled by a decrease in the number ofNgn3-expressing cells (4728±408 vs. 959±28; P<0.01). Finally, L-Leucine also caused a dose-dependent repressive effect on the mRNA levels of the three genes, namelyNgn3, its target Insm1, and insulin[1].
Leucine stimulates protein synthesis in skeletal muscle of neonatal pigs by enhancing mTORC1 activation. L-Leucine increases intracellular HIF-1α levels and activates the HIF-1α signaling pathway, and these two effects are mediated by the mTOR signaling pathway. This process results inNgn3repression and, consequently, decreases β-cell differentiation[1].
L-leucine stimulates mTORC1 by through a mechanism that involves the leucyl tRNA synthase promoting the activity of GTP activating proteins that act on mTORC1[2].
|
体内研究
(In Vivo) | L-Leucine (24 g/kg diet) combined with Resveratrol (12.5 mg/kg diet) to diet-induced obese (DIO) mice increases adipose Sirt1 activity[2].
Combination results in significant reductions in body weight, weight gain, visceral adipose tissue mass, fat oxidation and heat production in mice[2].
| Animal Model: | Six-week-old male c57/BL6 mice (fed a high-fat diet with fat to induce obesity)[1] | | Dosage: | 24 g/kg diet; Resveratrol (low dose; 12.5 mg/kg diet) | | Administration: | 6 weeks | | Result: | Treatment in combination with Resveratrol (low dose; 12.5 mg/kg diet) resulted in significant reductions in body weight, weight gain, visceral adipose tissue mass, fat oxidation and heat production, and an associated decrease in respiratory exchange ratio (RER), especially in the dark (feeding) cycle. |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 结构分类 | |
| 来源 | - Plants
- Gramineae
- Zea maysL.
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: H2O : 8.33 mg/mL(63.51 mM;Need ultrasonic) 配制储备液 | 1 mM | 7.6237 mL | 38.1185 mL | 76.2369 mL | | 5 mM | 1.5247 mL | 7.6237 mL | 15.2474 mL | | 10 mM | 0.7624 mL | 3.8118 mL | 7.6237 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： PBS Solubility: 6.25 mg/mL (47.65 mM); Suspended solution; Need ultrasonic and warming and heat to 60℃
*以上所有助溶剂都可在本网站选购。 |
